

U.S.S.N. 10/792,302
Filed: March 3, 2004
AMENDMENT AND RESPONSE TO OFFICE ACTION

Remarks

Amendments to the Claims

The claims in this case are drawn to a method for separating spore-like cells from differentiated cells, by exposing a mixture of the cells to conditions that kill the differentiated cells but not the spore-like cells. Independent claim 1 has been amended to define the conditions that kill normal differentiated cells but not the spore-like cells. The dependent claims now more specifically also define the features of the cells, such as the amount of nuclear material, the size, and the lack of differentiation. Support for the amendments is found at page 6, lines 12-29; page 15, lines 19-23; page 18, lines 1-25 (conditions to kill differentiated cells), page 7, lines 7-12 (separation by filtration); page 14, lines 20-28 (spore like cells are multipotent); page 14, line 29 to page 15, line 2; page 15, lines 15-18; page 16, line 29 to page 17, line 17; see also Figures 1 and 2 (size, amount of nucleus).

Rejections under 35 U.S.C. 112

Claims 1-29 were rejected under 35 U.S.C. 112 as failing to comply with the written description requirement and definiteness. These rejections are respectfully traversed if applied to the amended claims.

The principal basis of the rejection is that the spore-like cells are not clearly defined. It is believed this aspect of the rejection has been mooted by defining the conditions that are used to kill the differentiated cells but not

U.S.S.N. 10/792,302
Filed: March 3, 2004
AMENDMENT AND RESPONSE TO OFFICE ACTION

the spore-like cells, and defining the distinguishing characteristic separating the two types of cell as that multi- or pluripotent spore-like cells remain viable when exposed to the specific conditions, and the differentiated cells do not, as well as by describing in the specification the size, nuclear structure, and phenotypic characteristics of the spore-like cells, including actual SEMs of these cells from different tissues of origin (see examples 11 and 12, page 38). The examples clearly demonstrate that the claimed method was actually reduced to practice with a variety of different means of killing the differentiated cells but not the spore-like cells, and that the cells could then be separated. This fully complies with the written description requirement.

Example 1 demonstrates that spore-like cells were isolated from human blood (first species, first cell type) using repeated passaging in cell culture.

Example 2 demonstrates that spore-like cells were isolated from rat (species 2) skin (second cell type). The technique used for all of examples 2-10 was size separation (passaging through smaller and smaller bore pipets) followed by passaging in cell culture.

Example 3 demonstrates that spore-like cells were isolated from rat heart (third cell type).

Example 4 demonstrates that spore-like cells were isolated from rat intestine (fourth cell type).

U.S.S.N. 10/792,302
Filed: March 3, 2004
AMENDMENT AND RESPONSE TO OFFICE ACTION

Example 5 demonstrates that spore-like cells were isolated from rat bladder (fifth cell type) 2.

Example 6 demonstrates that spore-like cells were isolated from rat kidney (sixth cell type).

Example 7 demonstrates that spore-like cells were isolated from rat liver (seventh cell type).

Example 8 demonstrates that spore-like cells were isolated from sheep (third species) and rat lungs (eighth cell type).

Example 9 demonstrates that spore-like cells were isolated from rat adrenal glands (ninth cell type).

Example 10 demonstrates that spore-like cells were isolated from human and rat pancreas (tenth cell type).

Examples 13 and 14 demonstrate that spore-like cells were isolated from rat lung, liver, fascia, and spinal cord (four tissues, including two additional cell types) using enzyme digestion, storage in the refrigerator or freezer without supplemental oxygen (second technique) and passage through smaller and smaller pipets.

Example 15 demonstrates that spore-like cells were isolated from rat lung, liver, fascia, and spinal cord by heating to 85°C (third technique).

Trypan blue uptake was used to differentiate the viable from the dead cells.

Example 17 demonstrates isolation of spore-like cells from human blood that had been stored frozen for eight years and then were repeatedly

U.S.S.N. 10/792,302
Filed: March 3, 2004
AMENDMENT AND RESPONSE TO OFFICE ACTION

frozen and unfrozen, and separated by passage through filters and pasteur pipets.

In summary, spore-like cells were isolated using three completely different techniques: size separation and passage through cell culture; storage in the substantial absence of oxygen; and heating. Spore-like cells were isolated from three different species: human, rat and sheep. Finally, spore-like cells were isolated from twelve different cell types: blood, lung, liver, adrenal gland, fascia, spinal cord, skin, pancreas, kidney, bladder, intestine, and heart. The cells were characterized functionally, histologically, by SEM, and by phenotype.

The claims now provide a simple, easy and definitive means for practicing the method: one simply performs one or more of the recited means for killing differentiated cells but not spore-like cells, and then retains the viable cells, which are by definition the spore-like cells.

DEC. 2, 2004 6:10PM PABST PATENT GROUP

NO. 2391 P. 14

U.S.S.N. 10/792,302
Filed: March 3, 2004
AMENDMENT AND RESPONSE TO OFFICE ACTION

Allowance of claims 1-27, as amended, is respectfully solicited.

Respectfully submitted,



Patricia L. Pabst
Reg. No. 31,284

Date: December 1, 2004
PABST PATENT GROUP LLP
400 Colony Square, Suite 1200
1201 Peachtree Street
Atlanta, Georgia 30361
(404) 879-2151
(404) 879-2160 (Facsimile)